ASCO abstracts offer window into key oncology themes

As the industry’s major players begin to release their curtain raisers, presentation schedules and abstracts ahead of ASCO’s annual meeting, it’s possible to gain some insight into the likely key themes at this year’s event.

Reading the runes, EP Vantage notes the significance of promised data from Swiss pharma giant Roche’s (ROG: SIX) Perjeta (pertuzumab) program into breast cancer.

The trial, from which the company released positive new data in March showing the primary endpoint had been been met, is seen as a potential predictor for the future of a rival program from USA-based Puma Biotechnology (NYSE: PBYI).